NurExone Biologic Inc. reports financial results, including development progress and expenditures

From GlobeNewswire: 2024-08-28 08:34:00

NurExone Biologic Inc. announces its financial and operational results for the three and six months ending June 30, 2024. Key highlights include a contract for preclinical testing of its ExoPTEN drug, shares being listed on OTCQB Venture Market, and expansion of patent coverage in Japan.

In the second quarter of 2024, research and development expenses were $0.51 million, general and administrative expenses were $0.81 million, and finance expenses were $0.01 million. The net loss for the quarter was $1.33 million, with cash and cash equivalents totaling $2.39 million and working capital at $2.24 million as of June 30, 2024.

NurExone Biologic Inc. is developing exosome-based therapies, with its first product, ExoPTEN, targeting acute spinal cord injury. The platform aims to offer noninvasive drug delivery solutions and has been granted Orphan Drug Designation by the FDA. For more information about the company, visit www.nurexone.com.



Read more at GlobeNewswire:: NurExone Reports Second Quarter 2024 Financial Results and